Medidata, a subsidiary of Dassault Systèmes, has officially launched Medidata Plus, a new AI-native foundation designed to streamline and scale clinical trial portfolios. The platform integrates advanced artificial intelligence to assist researchers in managing complex data sets and accelerating the drug development lifecycle. By focusing on an AI-first architecture, the system aims to reduce the time and cost associated with clinical research while improving data accuracy. This release represents a strategic shift for the company as it looks to automate more aspects of pharmaceutical development through machine learning. How much impact will AI-native platforms like Medidata Plus have on the speed of clinical trials?
